Amantadine versus biperiden: A double-blind study of treatment efficacy in neuroleptic extrapyramidal movement disorders

Neuropsychobiology

Volumn 33, Issue 2, 1996, Pages 80-84

  Konig P ^a   Chwatal, K ^b   Havelec, L ^b   Riedl, F ^a   Schubert, H ^a   Schultes, H ^c  

^a Psychiatric Hospital   (Austria)

^b UNIVERSITY OF VIENNA   (Austria)

^c Psychiatric Practice   (Austria)

Author keywords

Amantadine; Anticholinergics; Glutamatergic system; Neuroleptic parkinsonism; Side effects

Indexed keywords

AMANTADINE; BIPERIDEN; CHOLINERGIC RECEPTOR BLOCKING AGENT; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT;

AGITATION; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED DISEASE; DYSPHORIA; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HUMAN; MALE; MOOD; MOTOR DYSFUNCTION; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; TARDIVE DYSKINESIA;

AMANTADINE; BIPERIDEN; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MOVEMENT DISORDERS; SCHIZOPHRENIA; TIME FACTORS;

EID: 0029924299     PISSN: 0302282X     EISSN: 14230224     Source Type: Journal    
DOI: 10.1159/000119254     Document Type: Article

References (23)

1. Van Putten T: Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974:31:67-72.
2. Van Putten T, May PRA, Marder SR: Response to antipsychotic medication: The doctors’s and the consumer's view, Am J Psychiatry 1984;141:16-20.
3. Winslow RS, Stiller V, Coons DJ, Robinson MW: Prevention of acute dystonic reactions in patients beginning high-potcncv neuroleptics, Am J Psychiatry 1986;143:706-710.
4. Greil W, Haag H, Rüther E: Spätdyskinesie: Untersuchungen zur Entstehung und Behandlung; in Bender W, Dencker SJ, Kulhanek K (eds): Schizophrene Erkrankungen, Therapie, Therapieresistenz - eine Standortbestimmung, Braunschweig, Vieweg, 1988, pp 124-131.
5. Pullen GP, Best NR, Maguire J: Anticholinergic drug use - A common problem? Br Med J 1984;289:612-613.
6. Langsiet A: Cardiac effects of antiparkinsonian drugs, local anaesthetics and tranquilizers, Eur J Pharmacol 1970;9:269-275.
7. Schwab RS, England JR, Snider SR: Amantadine in the treatment of Parkinson's disease, J Am Med Assoc 1969:208:1168-1170.
8. Streifler M, Avrami E: Levodopa and the secretion of sebum in parkinsonian patients, Eur Neurol 1990:9:43-48.
9. McEvoy J P: A double-blind crossover comparison of antiparkinsonian drug therapy: Amantadine versus anticholinergics in 90 normal volunteers with an emphasis on differential effects of memory function, J Clin Psychiatry 1987:84 (suppl):20-23.
10. Borison RL: Amantadine in the management of cxtrapyramidal side effects, Clin Neurophar-macol 1983:6:57-63.
11. Simpson GM, Angus JWS: Drug-induced extrapyramidal disorders, Acta Psychiatr Scand Suppl 1970:212.
12. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale, Psychol Rep 1962;10:799-812.
13. Binz U, Wendt G: KUSTA, Kurz-Skala Stimmung/Aktivierung, Manual, Weinheim, Beltz Test GmbH, 1983.
14. Fischcr-Comclssen KA; Clinical assessment and evaluation of side effects: An ethical question, CINP, Florence 1990, abstr F225.
15. Kornhubcr J, Weller M, Schoppemeyer K, Riederer P: Amantadine and mcmantine are NMDA receptor antagonists with neuroprotec-tivc properties, J Neural Transm 1994; 43(suppl):91-104.
16. Riederer P, Lange KW, Komhuber J, Daniel-czyk W: Glutamaicrgie-dopaminergic balance in the brain, Drug Res 1992:42:265-268.
17. Komhuber J: Adamantanamine: Neurobio-chemic und Wirkmechanismus: in Riederer P, I.aux G, Pöldinger W (eds): Neuro-Psycho-pharmaka, Wien, Springer, 1992, vol 5, pp 59-67.
18. Komhuber J, Weller M: Amantadine and the glutamate hypothesis of schizophrenia, Experiences in the treatment of neuroleptic malignant syndrome, J Neural Transm (Gen Sect) 1993; 92:57-65.
19. Klockgcther T, Turski L: Excitatory amino acids and the basal ganglia: Implications of the therapy of Parkinson’s disease, Trends Neuro-sci 1989:12:285-286.
20. Kornhubcr J, Weller M: Aktueller Stand der biochemischen Hypothesen zur Pathogenese der Schizophrenien, Nervenarzt 1994:65:741-754.
21. Streiflcr M: Klinik (Amantadine); in Riederer P, Laux G, Pöldinger W (eds): Neuro-Psvcho-pharmaka, Wien, Springer, 1992, vol 5, pp 59-67.
22. McEvoy JP, McCuc M, Fréter S: Replacement of chronically administered anticholinergic drugs by amantadine in outpatient management of chronic schizophrenia, Clin Ther 1987;9:429-433.
23. Carlsson M, Carlsson A: Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson’s disease, Trends Neurosci 1990;13:272-275.